Neuphoria Therapeutics
NEUP
8 hedge funds and large institutions have $1.1M invested in Neuphoria Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
33% less funds holding
Funds holding: 12 → 8 (-4)
37% less capital invested
Capital invested by funds: $1.74M → $1.1M (-$640K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$242K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.5K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$4.03K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$198 |
| 5 |
Morgan Stanley
New York
|
+$71 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$33K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$26.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$20K |
| 4 |
LAM
Lewis Asset Management
Lafayette,
California
|
-$17.6K |
| 5 |
Two Sigma Investments
New York
|
-$12.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $700K | +$242K | +30,520 | +30% |
|
|
LCM
2
Lynx1 Capital Management
San Juan,
Puerto Rico
| $241K | -$33K | -4,167 | -8% |
|
3
Point72 Asset Management
Stamford,
Connecticut
| $139K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $14.9K | +$22.5K | +2,845 | New |
|
|
5
RhumbLine Advisers
Boston,
Massachusetts
| $3.61K | +$4.03K | +509 | +278% |
|
|
6
Morgan Stanley
New York
| $393 | +$71 | +9 | +14% |
|
|
7
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $133 | +$198 | +25 | New |
|
|
APC
8
Aspire Private Capital
Cornelius,
North Carolina
| $88 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$26.8K | -2,908 | Closed |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$20K | -2,170 | Closed |
|
|
LAM
11
Lewis Asset Management
Lafayette,
California
| – | -$17.6K | -1,917 | Closed |
|
|
12
Two Sigma Investments
New York
| – | -$12.6K | -1,364 | Closed |
|
|
XT
13
XTX Topco
George Town,
Cayman Islands
| – | -$8.39K | -912 | Closed |
|
|
BPA
14
Beacon Pointe Advisors
Newport Beach,
California
| – | -$7.67K | -833 | Closed |
|
NEUP Hedge Fund Activity: Q3 2024 in Review
8 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q3 2024, worth a combined $1.1M — down 37% from $1.74M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NEUP and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, adding an estimated $242K. The largest seller was Lynx1 Capital Management, cutting an estimated $33K.
- 8 institutional investors held Neuphoria Therapeutics (NEUP) as of Q3 2024, down from 12 in Q2 2024.
- Funds reported $1.1M of Neuphoria Therapeutics stock for Q3 2024, down 37% quarter-over-quarter.
- 2 funds opened new Neuphoria Therapeutics positions in Q3 2024 and 6 closed out, a net change of -4 holders.
- The largest Neuphoria Therapeutics buyer in Q3 2024 was Armistice Capital, an estimated $242K added.
- The largest Neuphoria Therapeutics seller in Q3 2024 was Lynx1 Capital Management, an estimated $33K sold.
Based on aggregated 13F filings for Q3 2024.